linjc16/ctgov huggingface dataset:
Feasibility Testing of 7-Tesla Magnetic Resonance Imaging

Study Overview
=================
Brief Summary
-----------------
The goal of the current project is to explore and develop the technical feasibility of non-invasive imaging of the human musculoskeletal system and head with the first 7T MR scanner with a CE mark to identify areas where the higher field promises significant benefits in qualitative image quality. For a subset of the planned exams, state-of-the art 7T or 3T images will be used as standard of reference to comparatively gauge the qualitative image quality of the investigational 7T images.

Official Title
-----------------
Explorative Technical Feasibility Testing of 7-Tesla Magnetic Resonance Imaging of the Musculoskeletal System and of the Head

Conditions
-----------------
Magnetic Resonance Imaging

Intervention / Treatment
-----------------
* Other: 7 T MRI vs 3 T MRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Consent to undergo a 7T (and, if appropriate a comparative 3T) MRI exam. For some of the consistent small series: presence of a specific condition of the musculoskeletal system or of the head. This can include traumatic or degenerative changes, e.g., of tendons, cartilage, muscle, peripheral nerves, ligaments, and bones, or in the brain, as well as focal lesions, e.g., tumors. Exclusion Criteria: Contraindications to undergo a MRI examination at a field strength of 7 Tesla or at 3 Tesla. Irregular anatomy and/or tissue properties Inability to consent - for any reason. Body mass above 200 kg. Body mass below 30 kg. Women: pregnancy. Age below 18. Known or suspected non-compliance, drug or alcohol abuse. Inability to follow the procedures of the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 7 T MRI<br> | Other: 7 T MRI vs 3 T MRI<br>* Adult healthy and patient volunteers will undergo a ca. 1 hour examination of non-invasive magnetic-resonance imaging at 7T, and, if appropriate, a closely matching examination at 3T as a standard of reference.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Qualitative image quality of 7 T MRI | Current-day feasibility of various types of MR examinations of the human musculoskeletal system. The primary outcomes of small consistent series of the study are visual gradings and qualitative measures of image quality. Image quality is rated by independent readers using Likert scales. | through study completion, an average of 1 year |
Circadian and Seasonal Variation in Acute Myocardial Infarction

Study Overview
=================
Brief Summary
-----------------
Circadian and seasonal variation in acute myocardial infarction .

Detailed Description
-----------------
Circadian and seasonal variation in acute myocardial infarction and relation between circadian rhythm and seasonal variations with biological and physiological markes of normal human being.

Official Title
-----------------
Circadian and Seasonal Variation in Acute Myocardial Infarction in Relation to Blood Viscosity and Outcome Among Adults Attending the Main Assiut University Hospital

Conditions
-----------------
Myocardial Infarction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1.All patients above (16) years old 2.Complaint occur during acute climate changes Exclusion Criteria: 1.Patients below 16 years old 2.Complaint during normal climate

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Circadian and seasonal variation in acute myocardial infarction | Reporting the presence or absence of difference in electrocardiogram ,Echo and d-Dimer between patients presented with acute myocardial infarction in different seasons. | Baseline |
A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced Malignancies

Study Overview
=================
Brief Summary
-----------------
In this study, we collected the data of immunohistochemistry, gene detection, image, OS, PFS, Orr, and so on. Secondly, the database of immunotherapy for malignant tumor was established, and the predictive model was constructed to verify and establish the rationality and validity of the biomarkers and predictive system of immunotherapy

Official Title
-----------------
A Multicenter, Multiomics, Non-interventional, Real-world Study of the Efficacy and Safety of Immune Checkpoint Inhibitors as First-line Therapy for Advanced Malignancies

Conditions
-----------------
Malignant Tumor, Immunotherapy, Artificial Intelligence

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Informed consent has been signed and, in the judgment of the investigator, the patient is able to comply with the study protocol and sign a written informed consent. the advanced malignant tumors (solid tumors of the non-small-cell lung carcinoma, stomach, breast, urinary system, etc.) were diagnosed by histopathology. the stage IV according to the eighth edition of IASLC. PS 0-2, the expected survival > 3 months. the age of 18-75 years. no contraindication to treatment with immune checkpoint inhibitors. Exclusion Criteria: the patients' compliance was poor, which violated the rules of the trial; the patients with severe dysfunction of vital organs (heart, liver and kidney) ; the patients with other malignant tumors; the researchers considered that the patients should not participate in other conditions of the trial.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival | The time between randomization and the first occurrence of disease progression or death from any cause | six months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival | Time from randomization to death from any cause | two years | 
| Objective response rate | Proportion of patients whose tumors have shrunk to pre-defined volumes and who are able to maintain minimum time requirements | one years | 
| Immune-Related Adverse Events | In clinical trials of antineoplastic drugs/therapies, all levels of adverse drug reactions that are judged to be related to immune mechanisms, | two years |
Neurophysiological Evaluation of Residual Cognitive Functions in Patients With Severe Alterations of Consciousness

Study Overview
=================
Brief Summary
-----------------
Identify potential markers of recovery through event-related potentials (ERPs) in the evolution of altered consciousness with potential ability to discriminate between different conditions of altered state of consciousness. Identify potential markers with prognostic value, in order to identify personalized and specific intensive rehabilitation paths based on the outcome indexes obtained.

Official Title
-----------------
Neurophysiological Approach for the Evaluation of Residual Cognitive Functions in Patients With Severe Alterations of Consciousness

Conditions
-----------------
Consciousness Disorder, Cognitive Impairment

Intervention / Treatment
-----------------
* Diagnostic Test: Neurowave Group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Glasgow Coma Scale (GCS) > 8; Level of Cognitive Scale (LCF) = 1-3; Signature of the consent from the family member and/or guardian. Exclusion Criteria: Failure to sign the consent of the family member and/or legal guardian; Patients with cranial anatomical alterations that do not allow the correct assembly of the electrodes, caps, etc.; Patients with absence of neurophysiological responses in visual evoked potentials (VEP) and with absence of peripheral waves (I-II wave) to acoustic potentials (PEA).
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Neurowave Group|Neurosensory stimulation will consist in the administration of pairs of stimuli consisting of emotionally significant images and sounds in the personal life history (two rare stimuli) alternating with neutral images and sounds devoid of emotional significance (two distracting stimuli|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Event-related evoked potentials(ERPs) | Event-related evoked potentials(ERPs) are variations of the electric potential deriving from a visual, somesthetic or auditory stimulus. | 24 months |
Primary Aesthetic Breast Augmentation: Comparative Study Between Breast Implants and Autograft of Adipose Tissue

Study Overview
=================
Brief Summary
-----------------
The use of autograft of adipose tissue for aesthetic breast augmentation is increasing year after year. According to the latest meta-analysis of 2016, autograft of adipose tissue in augmentation mastoplasty seems to be a promising method with a satisfactory resorption volume and patient and surgeon satisfaction. However, this technique allows for small to moderate breast augmentation and is therefore not suitable for patients wanting a significant increase. Breast prostheses allow a significant increase. Numerous studies have shown an improvement in patient satisfaction and quality of life assessed using the BREAST-Q questionnaire. On the other hand, very few studies have objectively evaluated the satisfaction of patients who have benefited from an autograft of adipose tissue as part of aesthetic breast augmentation. No study has yet compared the satisfaction of patients who have benefited from breast implants or lipofilling. The aim of this study is to compare the satisfaction of patients who have benefited from breast augmentation by prosthesis or by lipofilling using a remote satisfaction interview.

Official Title
-----------------
Primary Aesthetic Breast Augmentation: Comparative Study Between Breast Implants and Autograft of Adipose Tissue

Conditions
-----------------
Breast Implants

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult woman (age ≥ 18 years) having benefited from primary aesthetic breast augmentation at Strasbourg University Hospital between June 27, 2017 and June 27, 2022 not opposing the reuse of its data for scientific research purposes. Exclusion Criteria: Woman who expressed her opposition to the reuse of her data for scientific research purposes Woman with a breast malformation: tuberous breasts or breast asymmetry of more than one cup Woman with comprehension difficulties Woman under guardianship or curatorship

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient woman satisfaction | This satisfaction will be assessed using a remote satisfaction interview | 1 to 4 years after breast implants | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Breast Prosthesis, Breast Implants
Mitochondrial Video Assessment Source Material Study

Study Overview
=================
Brief Summary
-----------------
Source material collection of videos to develop the Mitochondrial Video Assessment (MVA) for patients with mitochondrial myopathies.

Detailed Description
-----------------
This observational research is being conducted to facilitate the development of 2 related, disease-specific outcome measures assessing ease of movement in PMM and PolG clinical trials. The Mitochondrial Video Assessment (MVA) utilizes remote video capture to assess subtle shifts in compensatory movement patterns and measure change in function over time, and the Current State Questionnaire asks participants about external factors in their daily lives which may influence fluctuations in their symptoms. As part of the questionnaire, participants are asked to rate their own perception of their functional ability using a Patient Global Impression of Severity (PGI-S) scale.

Official Title
-----------------
Development of the Mitochondrial Video Assessment (MVA) as an Outcome Measure for the Evaluation of Patients With Mitochondrial Myopathies

Conditions
-----------------
PolG, Primary Mitochondrial Myopathy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 16 years old and above Confirmed diagnosis of PMM or PolG Ability to understand and speak English Ability and willing to consent Able and willing to participate and perform tasks while being recorded Designating a recording partner to assist with video captures is strongly advised, but not required Exclusion Criteria: N/A

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PolG<br>Genetically confirmed PoLG patients 16 years or older | |
| PMM<br>Genetically confirmed Primary Mitochondrial Myopathy patients 16 years or older | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Source Material Videos | Initiate feasibility testing and collect source material videos from patients with Primary Mitochondrial Myopathy (PMM, n=35) or a PolGamma (PolG) mutation (n=15) to facilitate development of the Mitochondrial Video Assessment (MVA). | 2 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PGI-S | Identify external factors which may influence participant performance on functional assessments and collect Patient Global Impression of Severity (PGI-S) at the time of each capture to facilitate the development of a patient-reported Current State Questionnaire to be deployed in conjunction with the MVA. | 2 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PoIG, Primary Mitochondrial Myopathy, MELAS, CPEO
Outcome of Surgical Fixation of Multiple Fractured Ribs at Sohag University Hospital

Study Overview
=================
Brief Summary
-----------------
The ribs are rigid and flexible structures that make up the chest skeleton and are a set of twelve paired bones. After Blunt trauma rib fractures incidence is about 30 to 40% [1]. Due to trauma, (4th -9th) ribs are often affected and the fracture point of the ribs is often on the midaxillary line. In ( 1st&2nd) ribs fractures subclavian vessels and brachial plexus damage may occur. In fractures in the lower ribs (8th-12th ribs), intra-abdominal organs injury such as liver, spleen and kidney should be investigated. 11-12. ribs fractures are rare because the ribs are more flexible (floating). Pain is the most important symptom indicating rib fracture, and it usually increases with coughing, breathing, and movement. Broken rib ends can be felt with palpation with sever tenderness at the site of fracture. Pneumothorax and/or hemothorax may develop as a result of the sharp end of the broken rib causing lung parenchymal damage[2].

Official Title
-----------------
Outcome of Surgical Fixation of Multiple Fractured Ribs at Sohag University Hospital

Conditions
-----------------
Multiple Fractures of Ribs

Intervention / Treatment
-----------------
* Procedure: surgical rib fixation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: multiple fractured ribs pre ventilation Exclusion Criteria: -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: intervention group<br>surgical fixation group | Procedure: surgical rib fixation<br>* open reduction and internal rib fixation<br>* Other names: open reduction and internal fixation;|
| No Intervention: control group<br>conservation group | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mechanical ventilation | the need and duration of mechanical ventilation | 1 year | 
| thoracic pain | measure severity of pain using pain scale 0 to10. | 1 year |
18F-FAPI PET/CT in Patients With Various Types of Cancer

Study Overview
=================
Brief Summary
-----------------
To evaluate the potential usefulness of 18F-FAPI positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer.

Detailed Description
-----------------
Subjects with various types of cancer underwent 18F-FAPI PET/CT either for an initial assessment or for recurrence detection. Tumor uptake was quantified by the maximum standard uptake value (SUVmax). Using histopathology and follow-up as gold standard, the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 18F-FAPI PET/CT were calculated.

Official Title
-----------------
The Performance of 18F-FAPI PET/CT in Patients With Various Types of Cancer

Conditions
-----------------
Cancer

Intervention / Treatment
-----------------
* Drug: 18F-FAPI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); patients who had scheduled 18F-FAPI PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: patients with non-malignant lesions; patients with pregnancy; the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 18F-FAPI<br>Experimental: Experimental: 18F-FAPI Each subject receive a single intravenous injection of 18F-FAPI, and undergo PET/CT imaging within the specificed time. | Drug: 18F-FAPI<br>* Each patient receive a single intravenous injection of 18F-FAPI, and undergo PET/CT scan within specified time.<br>* Other names: FAPI;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic accuracy | The sensitivity, specificity and accuracy of 18F-FAPI PET/CT were calculated. | 1 year |
Navigating the Clinical Trial Process for Hepatocellular Carcinoma

Study Overview
=================
Brief Summary
-----------------
Clinical trials can sometimes favor certain demographic groups. Additionally, there is limited research that delves into the factors that influence participation in clinical study, both positive and negative. The goal is to identify the obstacles and challenges that prevent participation in hepatocellular carcinoma clinical research, as well as the reasons for withdrawal or discontinuation. Insights gained from this study will ultimately benefit those with hepatocellular carcinoma who may be invited to participate in clinical research in the years to come.

Official Title
-----------------
A Critical Analysis of Hepatocellular Carcinoma Trials: Perspectives From Patient Experiences

Conditions
-----------------
Hepatocellular Carcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with hepatocellular carcinoma Willing to comply with all study related procedures and assessments Capable of giving signed informed consent, which includes compliance with requirements and restrictions listed in the informed consent form (ICF) and in the protocol Exclusion Criteria: No documented diagnosis of hepatocellular carcinoma Any serious and/or unstable pre-existing medical disorders Pregnant or lactating woman

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of patients who decide to enroll in a hepatocellular carcinoma clinical study. |  | 3 months | 
| Number of hepatocellular carcinoma study participants who remain in clinical trial until completion. |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hepatocellular carcinoma